Founded in 2002 and based in Strasbourg, France, NovAliX is a drug discovery-focused CRO supporting the drug discovery process from screening to optimized leads. With around 230 researchers, NovAliX provides strong capabilities in medicinal chemistry combined with screening platforms such as FBDD, covalent fragment screening and DEL. Experts offer in vitro pharmacology services and a unique biophysical and structural platform encompassing MS, SPR, NMR, MST, DSF, HDX, X-ray crystallography & cryo-EM — including membrane proteins. NovAliX also offers support in synthetic chemistry and chemical process research including a flow chemistry platform. CONTACT: info@novalix.com